Navigation Links
Celladon Corporation Receives FDA Fast Track Designation for Its Investigational Agent MYDICAR® for the Treatment of Heart Failure
Date:12/12/2011

LA JOLLA, Calif., Dec. 12, 2011 /PRNewswire/ -- Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, announced today that its investigational product candidate MYDICAR® has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of advanced heart failure.

The Fast Track program of the FDA is designed to facilitate the development and expedite the review of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs.

"The positive results of the phase 2 CUPID Trial demonstrated the potential of MYDICAR® to become an important treatment for patients with chronic, advanced heart failure," said Krisztina Zsebo Ph.D., President and CEO of Celladon Corp.  Dr. Zsebo continued, "Today we are pleased that the FDA recognizes the potential benefit of MYDICAR® to address the enormous unmet medical need for additional therapeutics to treat advanced heart failure patients by granting the program Fast Track Status."

About the CUPID Trial

The previously announced results of the phase 2 CUPID Trial met its primary safety and efficacy endpoints at 6 months for high dose MYDICAR® versus placebo. Additionally, 12 months after receiving a single infusion of MYDICAR®, patients treated with the highest dose versus placebo had an 88 percent risk reduction (Hazard Ratio = 0.12, P=0.003) of major cardiovascular events such as death, need for left ventricular assist device (LVAD) or cardiac transplant, episodes of worsening heart failure and number of heart failure-related hospitalizations.

The mean duration of hospitalization in the MYDICAR® high dose group during the 12-month period was 0.4 days per patient compared with 4.5 days per patient in the placebo group. This finding is especially n
'/>"/>

SOURCE Celladon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Celladon Corporation Announces MYDICAR® Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Reduction in Clinical Events in Patients for 18 Months Compared with Placebo
2. Celladon Provides MYDICAR(R) Program Update of First-In-Human Trial for Advanced Heart Failure at American Society of Gene Therapy Annual Meeting
3. Celladon Corporation Announces Presentation of First-in-Human Gene Transfer to Treat Heart Failure at the 12th Annual Meeting of the American Society of Gene Therapy
4. Celladon Announces Presentation of Clinical Data From First-in-Human MYDICAR(R) Trial for Advanced Heart Failure at American Heart Association Scientific Sessions
5. Leatt Corporation Announces 2011 Annual Shareholders Meeting
6. Angeion Corporation to Report Fourth Quarter and Fiscal Year 2011 Financial Results on Friday, December 16, 2011
7. Radient Pharmaceuticals Corporation Receives $500,000 in New Capital
8. Radient Pharmaceuticals Corporation Completes Restructurings with Institutional Investors to Limit Conversions and Stock Sales and Provide for Potential Additional Capital
9. China Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2012
10. Ansell Limited Acquires a Minority Share in Yulex Corporation
11. The Female Health Companys Distributor, Sekunjalo Investments Corporation (PTY) Ltd., Receives Order for 5 Million FC2 Female Condoms From the Republic of South Africa Department of Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... , Jan. 14, 2014 NineSigma , Inc., ... its Innovation Leadership Summit , May 14-16, 2014 ... Cleveland Ohio . This ... organizations committed to breakthrough achievements through open innovation. Participants ...
(Date:1/14/2014)... , January 14, 2014 Equashield ... for hazardous drugs, today announced that it has ... straight year.   Equashield,s closed systems ... pharmacists, nurses and other medical professionals who prepare ...
(Date:1/14/2014)... , Jan. 14, 2014 Spark Therapeutics , a late-stage ... most advanced clinical program, a Phase 3 study for inherited retinal ... CEO, Jeffrey D. Marrazzo , is presenting this and other ... in San Francisco . Marrazzo said Spark was ...
Breaking Medicine Technology:Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4Equashield's Sales Grow by 60% in 2013 2Spark Therapeutics Achieves Recruitment Goal in Phase 3 Gene Therapy Clinical Study for Inherited Blindness 2Spark Therapeutics Achieves Recruitment Goal in Phase 3 Gene Therapy Clinical Study for Inherited Blindness 3
... Jan. 11, 2011 A Blanchette Rockefeller Neurosciences ... of Neuroscience reveals underlying causes for the degeneration ... pharmaceutical solutions for the devastating condition that affects ... States. The BRNI study is the first to ...
... Hill-Rom Holdings, Inc. (NYSE: HRC ) will release ... 2011.  The company will host a webcast the following morning ... Earnings Release:   Hill-Rom,s Fiscal 2011 First Quarter ... be issued to the public after the close of the ...
Cached Medicine Technology:The Blanchette Rockefeller Neurosciences Institute Identifies Groundbreaking New Therapies for Prevention and Treatment of Alzheimer's Disease 2The Blanchette Rockefeller Neurosciences Institute Identifies Groundbreaking New Therapies for Prevention and Treatment of Alzheimer's Disease 3Hill-Rom Holdings, Inc. Hosts Fiscal 2011 First Quarter Earnings Webcast 2
(Date:4/24/2014)... TORONTO Baker,s yeast is giving scientists a better ... of hospitalization and illness world-wide. , When two ... one can suppress or enhance the effectiveness of the ... of another. These types of interactions are a major ... severe practical limits on the practical scope of drug ...
(Date:4/24/2014)... lenses coated with an antimicrobial peptide could help to lower ... Optometry and Vision Science , official journal ... journal is published by Lippincott Williams & Wilkins , ... in animals and now humans support the biocompatibility and safety ... the new research by Debarun Dutta, B.Optom, of The University ...
(Date:4/24/2014)... Center for BrainHealth will bring together national experts ... challenges at its inaugural Brain Health Summit, titled ... speakers will include Dr. Sandra Bond Chapman, founder ... U.S. Senator Chuck Grassley (R-IA), U.S. Representative Chaka ... for Policy and Early Learning, U.S. Department of ...
(Date:4/24/2014)... the corresponding terminology, and the relevance of palliation ... publications on randomized controlled trials (RCTs). This is ... Institute for Quality and Efficiency in Health Care ... report. , Together with external experts, IQWiG analysed ... lung cancer, malignant melanoma, and pancreatic cancer. For ...
(Date:4/24/2014)... than to receive at least if you,re an adolescent ... study found that 15- and 16-year-olds who find pleasure in ... are less likely to become depressed than those who get ... for themselves. , The researchers detail their findings in the ... The study focused on the ventral striatum, a brain region ...
Breaking Medicine News(10 mins):Health News:Large-scale identification and analysis of suppressive drug interactions 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 3Health News:Inaugural Brain Health Summit focuses on brain resilience and regeneration 2Health News:Palliation is rarely a topic in studies on advanced cancer 2Health News:Palliation is rarely a topic in studies on advanced cancer 3Health News:Study: Altruistic adolescents less likely to become depressed 2
... Demonstrate Deepening Relationship , Between Edwards and Primary Sponsor ... off its first year as primary sponsor of Carl ... big way with the launch of its latest television ... to air during the national broadcast of the Feb. ...
... Prevent Preterm BirthWHITE PLAINS, N.Y., Feb. 11 ... may cause preterm labor in some women, investigate ... contractions and an early birth, and look at ... environmental risk factors for prematurity.The work of seven ...
... and St George,s, University of London measured recent exposure to ... British Regional Heart Study by measuring the levels of cotinine ... time points 20 years apart. A blood cotinine level above ... of a heart attack (2), and other studies have suggested ...
... Results of a recent study conducted by researchers ... show that cognitive functioning abilities drop as average blood ... , The study appears in this month,s issue of ... Diabetes (MIND) study, a sub-study of the Action to ...
... French . , Montreal, February 11th, 2009 ... the nutrients the tumours receive through the blood. The team ... McGill University Health Centre (MUHC) at the Montreal Children,s Hospital, ... a new mechanism that tumours use to stimulate the growth ...
... world,s first phase one FDA-approved clinical trial using adult ... conducted by a team of University of Louisville ... with advanced heart disease who already are undergoing bypass ... trial, which uses adult stem cells taken from the ...
Cached Medicine News:Health News:New Ads Provide Glimpse Into Unique Friendship Between Aflac Duck and Carl Edwards 2Health News:New Ads Provide Glimpse Into Unique Friendship Between Aflac Duck and Carl Edwards 3Health News:New Ads Provide Glimpse Into Unique Friendship Between Aflac Duck and Carl Edwards 4Health News:March of Dimes Provides $2.7 Million in New Funding For Preterm Birth Research 2Health News:March of Dimes Provides $2.7 Million in New Funding For Preterm Birth Research 3Health News:Smokers putting their loved ones at risk of heart attacks 2Health News:Higher blood sugar levels linked to lower brain function in diabetics, study shows 2Health News:Innovative method to starve tumors 2Health News:World's First Cardiac Adult Stem Cell Trial to Take Place in Louisville 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: